Cutting-Edge Proteomics meets AI to Rejuvenate Cancer Immunotherapy
We discover novel drug targets and IO response markers by combining proteomics and computational biology
Protica Bio is a start-up company combining cutting-edge proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries to revolutionize diagnostic prediction and future treatment. The company is utilizing a proprietary platform developed by a leading expert in the field of Mass spectrometry from the Weizmann Institute. In addition to laboratory research, the company integrates deep proteomics with machine learning to create diagnostic capabilities and elevate the response rate for current and future treatments.
Treatment with immune checkpoint inhibitors (ICI), mainly anti-PD1, has revolutionized oncological therapy for selected patients with melanoma and lung cancer. However, the response rates in these and other solid tumors are still significantly lower. Therefore, it is critical to identify predictive markers of response (of specific drugs and drug combinations) and to identify novel drug targets for combination therapies with ICI.
Protica Bio aims to tackle these challenges by combining state-of-the-art proteomics technologies and supporting methods with computational biology. As proteomics allows identification and quantification of the tumor proteome in an unbiased manner and identify novel cancer regulators that cannot be found with other technologies, we believe that machine learning capabilities it’s the right approach to achieve breakthroughs in this domain.